Hallucinations associated with miglitol use in a patient with chronic kidney disease and hypothyroidism
Authors:
Open Access
- 9 February 2015
- journal article
- case report
- Published by BMJ in BMJ Case Reports
- Vol. 2015
Abstract
A 71-year-old woman with type 2 diabetes mellitus, chronic kidney disease stage IV, primary hypothyroidism and osteoarthritis, whose prescribed treatment included miglitol 50 mg thrice daily with the first bite of meals, reported that she suffered visual hallucinations while taking miglitol, which resolved within a few days of stopping the drug. When she resumed miglitol, hallucinations recurred within a few days and again resolved within a few days of stopping the drug. To our knowledge, this is the first reported case of hallucinations associated with the use of an α-glucosidase inhibitor and highlights a previously unappreciated risk associated with the use of this generally quite benign drug class.Keywords
This publication has 16 references indexed in Scilit:
- Comparing the Efficacy of α-Glucosidase Inhibitors in Suppressing Postprandial Hyperglycemia Using Continuous Glucose Monitoring: A Pilot Study—The MAJOR StudyDiabetes Technology & Therapeutics, 2011
- Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe diseaseJournal of Neurology, 2010
- Visual Hallucinations in a Patient with Adult Onset Acid Maltase Deficiency DisorderJournal of General Internal Medicine, 2009
- The effect of chronic renal failure on drug metabolism and transportExpert Opinion on Drug Metabolism & Toxicology, 2008
- Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe diseaseNeurology, 2008
- Cognitive Impairment in the Aging Dialysis and Chronic Kidney Disease Populations: An Occult BurdenAdvances in Chronic Kidney Disease, 2008
- Les Iminosucres : applications thérapeutiques actuelles et futuresAnnales Pharmaceutiques Françaises, 2007
- Hypothyroidism Presenting as PsychosisThe Primary Care Companion For CNS Disorders, 2003
- The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening dataDiabetes Care, 1998
- Influence of Thyroid Dysfunction on Drug PharmacokineticsClinical Pharmacokinetics, 1981